HYPMY — Hypermarcas S.A.

OTC · Unknown · Unknown · CIK 1486749 ·
Last close
$4.39
Market Cap
$3.09B
52W High
$5.44
52W Low
$3.81
ADV30
34,353
Next earnings
Hypera S.A. operates as a pharmaceutical company in Brazil. The company provides sweeteners products under the Adocyl, finn, and Zero-cal brands; analgesics and anti-inflammatories products under the Doril, Atroveran, Calminex, Alivium, Buscopan, Buscofem, geloll, Torsilax, Neosaldina, and naprohax brands; cold and flu remedies and decongestants products under BENEGRIO, Rinosoro, Blu, Neosoro, Coristina, APRACUR, and Fluviral brands. It offers antihistamines products under Alektos, Histamin, Polaramine, PredSim, and Desrinite brands; antiseptics products under Merthiolate brand; Herbal medicine products under Maracugina, Eparema, Tamarine, and Naturetti brands; gastrointestinal products under Dramin, Estomazil, Engov, Lacto-purga, gastrol, Epocler, Bifilax, and Pepsamar brands. In addition, the company provides generics products under neo quimica brand; skicare products under episol, epidrat, simple organic, and bioage brands; supplements and vitamins products Addera, Biotonico Fontoura, Colflex, and Vitasay brands; and other products under Nebacetin, Cepacol, ESCABIN, Mirrorelax, Ammy, Nesina, and Diprospan brands. The company was formerly known as Hypermarcas S.A. and changed its name to Hypera S.A. in February 2018. Hypera S.A. was founded in 1999 and is headquartered in São Paulo, Brazil.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 2,017,778,000 1,210,563,000 505,890,000 347,378,000 26,001,025,000 2,310,906,000 11,878,077,000
Dec 2025 2,237,067,000 1,378,122,000 650,293,000 450,989,000 25,158,004,000 1,645,541,000 12,633,630,000
Sep 2025
Jun 2025 2,153,937,000 1,295,086,000 643,349,000 426,689,000 24,237,607,000 1,203,615,000 12,243,222,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$2,241,731,000
Investing CF
$-684,825,000
Financing CF
$-1,645,474,000
CapEx
$-762,040,000
Dividends Paid
$-1,406,351,000
Buybacks
$-31,405,000
EPS Diluted TTM
$2.62
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$162,329,000
Inventory
$2,065,956,000
Receivables
ST Investments
EBIT TTM
$1,953,687,000
Pretax Income TTM
$1,149,338,000
Interest Exp TTM
$804,349,000
Analysts

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 7,699,157,000 1,738,049,000 1,195,369,000 25,158,004,000 12,633,630,000 2,574,431,000
Dec 2024 7,442,466,000 1,795,769,000 1,340,990,000 24,559,083,000 12,457,264,000 2,539,599,000
Dec 2023 7,914,658,000 2,497,918,000 1,647,960,000 24,508,751,000 12,990,878,000 2,395,993,000
Dec 2022 7,546,355,000 2,459,340,000 1,696,697,000 23,755,633,000 13,100,192,000 2,038,793,000

News headlines (Yahoo Finance, 1h cache)

Hypera SA (HYPMY) Q4 2025 Earnings Call Highlights: Record Cash Flow and Strategic Market Expansion
2026-03-21 01:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.